Back to Top Skip to main content Skip to sub-navigation

DOD participates in new COVID-19 antibody combination prevention trial

Image of Woman gets blood drawn. Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | MHS Toolkits and Branding Guidance

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

Does CSM Gragg Have COVID-19?

Video
2/9/2022
Does CSM Gragg Have COVID-19?

CSM Gragg demonstrates how to use a COVID-19 at home rapid test.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | At-Home COVID-19 Tests | Coronavirus & the MHS Response

CSM Gragg Vaccine Statement

Video
8/24/2021
CSM Gragg Vaccine Statement

CSM Gragg shares his personal story dealing with COVID and the loss associated with it and urges all to take precautions.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Coronavirus & the MHS Response | Getting the COVID-19 Vaccine

LTG Place on Vaccine Importance

Video
8/17/2021
LTG Place on Vaccine Importance

LTG Place presents his concerns over those who are still unvaccinated during these unprecedented times. Take the right steps to prevent tragedy befalling your family and schedule your vaccine today at https://tricare.mil/vaccineappointments.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

Lt. Gen. Place and Command Sgt. Maj. Gragg on Getting Vaccinated

Video
8/16/2021
Lt. Gen. Place and Command Sgt. Maj. Gragg on Getting Vaccinated

DHA Director Lt. Gen. Ron Place and DHA Senior Enlisted Leader Command Sgt. Maj. Michael Gragg talk about how getting vaccinated against COVID-19 is more important than ever.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts | Coronavirus & the MHS Response | Getting the COVID-19 Vaccine

The Battle Against the COVID-19 Delta Variant

Video
6/29/2021
The Battle Against the COVID-19 Delta Variant

Like our enemies in the past, the coronavirus has adapted and we're now dealing with the most transmissible variant yet, Delta. The fight can be won with vaccination. If you're not yet vaccinated against the coronavirus, go get your shot today. Otherwise you're at high risk for severe disease, hospitalization, and death.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

The Delta Variant: A New Reason to Get Vaccinated

Video
6/25/2021
The Delta Variant: A New Reason to Get Vaccinated

Are you a service member age 18 to 30? Are you unvaccinated? You may be entitled to severe disease, hospitalization, and death. To avoid these options, get vaccinated today!

Recommended Content:

Coronavirus & the MHS Response | COVID-19 Vaccine Efforts | Coronavirus and the COVID-19 Vaccine

Are mRNA vaccines safe?

Video
5/28/2021
Are mRNA vaccines safe?

Dr. LC Collins explains the years of research and ongoing monitoring to show how mRNA vaccines are safe and effective.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vax Facts | Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

VAX Facts: Breastfeeding after the COVID-19 Vaccine

Video
5/28/2021
VAX Facts: Breastfeeding after the COVID-19 Vaccine

Dr. LC Collins encourages people who are breastfeeding to get the vaccine. Since the vaccine doesn't contain live virus, you can't pass COVID to your baby.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vax Facts | Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

What is an mRNA vaccine?

Video
5/28/2021
What is an mRNA vaccine?

Dr. LC Collins explains how mRNA vaccines work to protect you from COVID-19.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vax Facts | Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

VAX Facts: Do I Need the Vaccine if I Had COVID?

Video
5/28/2021
VAX Facts: Do I Need the Vaccine if I Had COVID?

Dr. LC Collins talks about the importance of getting vaccinated even if you already had COVID. We're not sure how long natural immunity lasts, so getting vaccinated is the best way to protect yourself.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vax Facts | Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

VAX Facts: Which Vaccine is Right for Me?

Video
5/28/2021
VAX Facts: Which Vaccine is Right for Me?

Dr. LC Collins talks about the importance of getting the first vaccine available to you. Don't hold out for a certain brand; they're all safe and effective.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vax Facts | Coronavirus & the MHS Response | COVID-19 Vaccine Efforts

Town Hall May 26 2021

Video
5/26/2021
Town Hall May 26 2021

RADM Anne Swap will discuss the National Capital Region's response to COVID-19

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Coronavirus & the MHS Response | Direct Reporting Markets

Vax Facts: Recommendations for Pregnancy

Video
5/20/2021
Vax Facts: Recommendations for Pregnancy

The COVID vaccine is recommended for pregnant people. Watch to learn how your doctor can help you make the best decision for you and your baby.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts

Vax Facts: I'm fully vaccinated. What can I do?

Video
5/20/2021
Vax Facts: I'm fully vaccinated. What can I do?

If you're fully vaccinated, there are options for safer activities. Watch to learn what activities you can resume once you're fully vaccinated.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts

Vax Facts: Risk and Precautions

Video
5/20/2021
Vax Facts: Risk and Precautions

If you're fully vaccinated, there are options for safer activities. Watch to learn what activities you can resume once you're fully vaccinated.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | COVID-19 Vaccine Efforts
<< < 1 2 3 4 > >> 
Showing results 1 - 15 Page 1 of 4
Refine your search
Last Updated: August 30, 2021

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.